ligelizumab
Selected indexed studies
- Efficacy and safety of ligelizumab in adults and adolescents with chronic spontaneous urticaria: results of two phase 3 randomised controlled trials. (Lancet, 2024) [PMID:38008109]
- Ligelizumab for the treatment of chronic spontaneous urticaria. (Expert Opin Biol Ther, 2020) [PMID:32380864]
- Ligelizumab use for chronic spontaneous urticaria. (Lancet, 2025) [PMID:40713427]
_Worker-drafted node — pending editorial review._
Connections
No connections recorded yet.
Sources
- Efficacy and safety of ligelizumab in adults and adolescents with chronic spontaneous urticaria: results of two phase 3 randomised controlled trials. (2024) pubmed
- Ligelizumab for the treatment of chronic spontaneous urticaria. (2020) pubmed
- Ligelizumab use for chronic spontaneous urticaria. (2025) pubmed
- Ligelizumab for Chronic Spontaneous Urticaria. (2019) pubmed
- Autoimmune chronic spontaneous urticaria. (2022) pubmed
- The rationale for development of ligelizumab in food allergy. (2022) pubmed
- Efficacy and Safety of Ligelizumab in Chronic Spontaneous Urticaria: A Systematic Review and Meta-analysis of Randomized Controlled Trials. (2025) pubmed
- Ligelizumab for Chronic Spontaneous Urticaria. (2020) pubmed
- Ligelizumab for chronic spontaneous urticaria. (2020) pubmed
- Ligelizumab in adolescents with chronic spontaneous urticaria: Results of a dedicated phase 2b randomized clinical trial supported with pharmacometric analysis. (2023) pubmed